ストックスクリーナーアプリを入手
2.15
7.33%
-0.17
アフターアワーズ：
2.15
前日終値:
$2.32
開ける：
$2.32
24時間の取引高:
301.06K
Relative Volume:
1.11
時価総額：
$86.87M
収益：
-
当期純損益:
$-110.66M
株価収益率:
-0.6944
EPS:
-3.0963
ネットキャッシュフロー:
$-97.76M
1週間 パフォーマンス:
+6.44%
1か月 パフォーマンス:
-3.59%
6か月 パフォーマンス:
-55.21%
1年 パフォーマンス:
-86.13%
1日の値動き範囲:
$2.06
$2.3695
1週間の範囲:
$1.96
$2.3695
52週間の値動き範囲:
$1.78
$17.55
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
名前
Kyverna Therapeutics Inc
セクター
電話
(510) 626-8331
住所
5980 HORTON STREET, EMERYVILLE
KYTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KYTX
Kyverna Therapeutics Inc
|
2.15 | 86.87M | 0 | -110.66M | -97.76M | -3.0963 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.16 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.36 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
532.27 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
267.55 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
219.95 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-10 | 開始されました | UBS | Buy |
| 2024-10-09 | 開始されました | Rodman & Renshaw | Buy |
| 2024-07-03 | 開始されました | H.C. Wainwright | Neutral |
| 2024-03-04 | 開始されました | JP Morgan | Overweight |
| 2024-03-04 | 開始されました | Leerink Partners | Outperform |
| 2024-03-04 | 開始されました | Morgan Stanley | Overweight |
| 2024-03-04 | 開始されました | Wells Fargo | Overweight |
すべてを表示
Kyverna Therapeutics Inc (KYTX) 最新ニュース
Integral Health Asset Management LLC Acquires 150,000 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases - Seeking Alpha
Kyverna Therapeutics Provides Business Update And Reports First Quarter 2025 Financial Results - marketscreener.com
Kyverna's Autoimmune Pipeline Hits Major Milestones: SPS Trial Full, MG Phase 3 Gets FDA Green Light - Stock Titan
KYTX Stockholders Have Opportunity to Lead Kyverna Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Kyverna Therapeutics (KYTX) to Release Quarterly Earnings on Tuesday - MarketBeat
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics - ACCESS Newswire
Kyverna Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights – KYTX - ACCESS Newswire
Kyverna Therapeutics Inc expected to post a loss of $1.11 a shareEarnings Preview - TradingView
Class Action Filed Against Kyverna Therapeutics, Inc. (KYTX)February 7, 2025 Deadline to Join – Contact Levi & Korsinsky - ACCESS Newswire
KYVERNA THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Ky - ACCESS Newswire
Shareholders that lost money on Kyverna Therapeutics, Inc.(KYTX) should contact Levi & Korsinsky about pending Class ActionKYTX - ACCESS Newswire
Shareholders that lost money on Kyverna Therapeutics, Inc.(KYTX) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More - ACCESS Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Kyverna Therapeutics, Inc. (KYTX) Shareholders - ACCESS Newswire
Shareholders of Kyverna Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your RightsKYTX - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Brokerages Set Kyverna Therapeutics, Inc. (NASDAQ:KYTX) PT at $18.33 - MarketBeat
Kyverna Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your RightsKYTX - ACCESS Newswire
KYTX Stock Price and Chart — NASDAQ:KYTX - TradingView
Gilead Sciences Inc. Purchases New Position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
JPMorgan Chase & Co. Sells 220,915 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Sold by Franklin Resources Inc. - MarketBeat
Notice to Long-Term Shareholders of Kyverna Therapeutics, - GlobeNewswire
Notice to Long-Term Shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Methode - Bluefield Daily Telegraph
Notice to Long-Term Shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Methode Electronics, Inc. (NYSE: MEI); ModivCare, Inc. (NASDAQ: MODV); and Monolithic Power Systems, Inc. (NASDAQ: MPWR)Grabar Law Office Is Investigating Claims - TradingView
Investigation announced for Long-Term Investors in shares of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) - openPR.com
Kyverna Therapeutics Inc (KYTX) 財務データ
収益
当期純利益
現金流量
EPS
Kyverna Therapeutics Inc (KYTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Jones Ryan Alexander | Chief Financial Officer |
May 28 '24 |
Option Exercise |
0.73 |
18,016 |
13,152 |
43,950 |
0.15%
大文字化:
|
ボリューム (24 時間):